Antag Therapeutics Funding: $86M Raised, Series A (2024)
Antag Therapeutics is a Biotech company. It has raised $86M in total funding. Latest round: Series A. Backed by Versant Ventures, Novo Holdings, SR One.
Antag Therapeutics funding overview
Antag Therapeutics is a Biotech company. Antag Therapeutics has raised $86M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in December 2024. The round record for Antag Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Versant Ventures, Novo Holdings, SR One, Dawn Biopharma, Pictet. 5 distinct backers are named across the disclosed rounds.
Antag Therapeutics at a glance
Total raised
$86M
Latest round
Series A
Latest round date
December 2024
Industry
Biotech
Notable investors
Versant Ventures, Novo Holdings, SR One, Dawn Biopharma, Pictet
Frequently asked about Antag Therapeutics funding
How much has Antag Therapeutics raised?
Antag Therapeutics has raised $86M in total disclosed funding across the rounds on record.
Who has invested in Antag Therapeutics?
Versant Ventures, Novo Holdings, SR One, Dawn Biopharma, Pictet are named among the investors backing Antag Therapeutics.
What was the latest Antag Therapeutics funding round?
The most recent disclosed round is a Series A, announced in December 2024.
Where is Antag Therapeutics based?
No headquarters location is disclosed for Antag Therapeutics.
What sector does Antag Therapeutics operate in?
Antag Therapeutics is tracked under Biotech, with $86M in disclosed funding.
When did Antag Therapeutics last raise?
The last disclosed Antag Therapeutics round closed in December 2024 at Series A.
Totals shown for Antag Therapeutics aggregate every disclosed round on file. To see how that compares, browse the Biotech companies and the investors behind them below.
